

References

I-94

1. Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. *Cochrane Database Syst Rev*. 2014;10:CD007419.
2. The Diabetic Retinopathy Clinical Research N. aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med*. 2015;372(13):1193-1203.
3. Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. *Ophthalmology*. 2015;122(2):367-374.
4. Andreoli MT, Pinnolis M, Kieser T, Sun J, Andreoli CM. Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. *J Ophthalmol*. 2015;29-34.
5. Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema. *JAMA Ophthalmol*. 2016;134(1):95–99.
6. Li E, Greenberg PB, Voruganti I, Krzystolik G. Cost and selection of ophthalmic anti-vascular endothelial growth factor agents. *R I Med J*. 2016;15-16.
7. Eyle® (aflibercept) injection, for intravitreal use [package insert]. Regeneron Pharmaceuticals, Inc. Tarrytown, NY. Revised 06/2021.
8. Macugen® (pegaptanib sodium injection) injection, for intravitreal use [package insert]. Bausch + Lomb Inc., Bridgewater, NJ. Revised 07/2016.
9. Lucentis® (ranibizumab injection) injection, for intravitreal use [package insert]. Genentech, Inc., South San Francisco, CA. Revised 03/2018.
10. Jetrea® (ocriplasmin) injection, for intravitreal use [package insert]. ThromboGenics Inc., Iselin, NJ. Revised 02/2017.
11. Avastin (bevacizumab) injection, for intravitreal use [package insert]. Genentech, Inc., South San Francisco, CA. Revised 06/2019.
12. Clinical Pharmacology™ Compendium. [database online]. 2022. Tampa FL: Gold Standard, Inc. aflibercept.
13. Clinical Pharmacology™ Compendium. [database online]. 2022. Tampa FL: Gold Standard, Inc. pegaptanib sodium.
14. Clinical Pharmacology™ Compendium. [database online]. 2022. Tampa FL: Gold Standard, Inc. ranibizumab injection.
15. Clinical Pharmacology™ Compendium. [database online]. 2022. Tampa FL: Gold Standard, Inc. ocriplasmin.
16. Clinical Pharmacology™ Compendium. [database online]. 2022. Tampa FL: Gold Standard, Inc. bevacizumab.
17. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. *JAMA*. 2015;314(20):2137-2146.

18. Clinical Pharmacology™ Compendium. [database online]. 2022. Tampa FL: Gold Standard, Inc. Brolucizumab-dblI.
19. Beovu® (brolucizumab-dblI) injection, for intravitreal use [package insert]. Novartis Pharmaceuticals Corp., East Hanover, NJ. Revised 3/2022.
20. Micromedex DrugDex Compendium®. 2022. Bevacizumab.
21. Dugel P, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. *Ophthalmology*. 2020;127:72-84.
22. Cheung C, Arnold J, Holz F, et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. *Ophthalmology*. 2017;124:1690-1711.
23. Micromedex DrugDex Compendium®. 2022. Brolucizumab.
24. Micromedex DrugDex Compendium®. 2022. Ranibizumab.
25. Micromedex DrugDex Compendium®. 2022. Pegaptanib.
26. Micromedex DrugDex Compendium®. 2022. Aflibercept.
27. Micromedex DrugDex Compendium®. 2022. Ocriplasmin.
28. Micromedex DrugDex Compendium®. 2022. Faricimab-svoa.
29. Clinical Pharmacology Compendia. [database online]. 2022. Tampa FL: Gold Standard, Inc. Faricimab
30. Susvimo™ (ranibizumab injection) intravitreal injection via ocular implant [package insert]. Genentech Inc., South San Francisco, CA. Revised 10/2021.
31. Byooviz® (ranibizumab-nuna) injection, for intravitreal use [package insert] Biogen Inc., Cambridge, MA. Revised 9/2021.
32. Vabysmo™ (faricimab-svoa) injection, for intravitreal use [package insert]. Genentech Inc., South San Francisco, CA. Revised 01/2022.
33. Aflibercept In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 1, 2022.
34. Brolucizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 20, 2020.
35. Faricimab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 1, 2022.
36. Ocriplasmin In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 30, 2013
37. Pegaptanib In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 1, 2009.

38. Ranibizumab. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 1, 2022.
39. Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: The STAIRWAY phase 2 randomized clinical trial. *JAMA Ophthalmol.* 2020;138(9):964-972.
40. Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD Phase 2 randomized trial. *Ophthalmology.* 2019;126(8):1155-1170.
41. Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: A randomized clinical trial. *JAMA Ophthalmol.* 2021;139(1):68-76.
42. Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. *Ophthalmology.* 2022;129(3):295-307.